SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bergh J) "

Sökning: WFRF:(Bergh J)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Iurilli, M. L. C., et al. (författare)
  • Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight NCD Risk Factor Collaboration (NCD-RisC)
  • 2021
  • Ingår i: eLife. - : eLife Sciences Publications Ltd. - 2050-084X. ; 10
  • Tidskriftsartikel (refereegranskat)abstract
    • From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia and sub-Saharan Africa, the underweight tail of the BMI distribution was left behind as the distribution shifted. There is a need for policies that address all forms of malnutrition by making healthy foods accessible and affordable, while restricting unhealthy foods through fiscal and regulatory restrictions.
  •  
2.
  •  
3.
  •  
4.
  • Abe, O, et al. (författare)
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  • 2005
  • Ingår i: The Lancet. - : Elsevier. - 1474-547X. ; 365:9472, s. 1687-1717
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • van der Lee, S. J., et al. (författare)
  • A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity
  • 2019
  • Ingår i: Acta Neuropathologica. - 0001-6322. ; 138:2, s. 237-250
  • Tidskriftsartikel (refereegranskat)abstract
    • The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLC gamma 2 pathway as drug-target.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (535)
konferensbidrag (163)
forskningsöversikt (7)
bokkapitel (3)
annan publikation (3)
rapport (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (493)
övrigt vetenskapligt (218)
populärvet., debatt m.m. (1)
Författare/redaktör
Bergh, J (509)
Foukakis, T (65)
Hatschek, T (40)
Cardoso, F (38)
Hartman, J (36)
Tobin, NP (28)
visa fler...
Cameron, D. (27)
Lindman, H (27)
Hall, P (26)
Harbeck, N (25)
Piccart, M (24)
Holmberg, L (23)
Bergh, C. (23)
Wilking, N (23)
Bergh, Christina, 19 ... (22)
Gnant, M. (21)
Blomqvist, C (20)
Czene, K (19)
Fornander, T (19)
Klaar, S (18)
Lidbrink, E (18)
Norton, L (17)
Bengtsson, NO (17)
Ahlgren, J (17)
Cortes, J (17)
Smeds, J (17)
Johansson, H (16)
Bogaerts, J (16)
Bergh, A (16)
Jassem, J. (16)
Nygren, P (16)
Piccart, MJ (15)
Wilking, U (15)
Viale, G (15)
Untch, M (15)
Brandberg, Y (15)
Loibl, S (15)
Jonsson, B (14)
Malmstrom, P (14)
Karlsson, E (14)
Skoog, L (14)
Schmid, P. (13)
Soderberg, M (13)
Costa, A. (13)
Gray, R (13)
Gelmon, K (13)
Larsson, R (13)
Linderholm, B (13)
Sodersten, P (13)
Lindgren, A. (13)
visa färre...
Lärosäte
Karolinska Institutet (509)
Uppsala universitet (122)
Göteborgs universitet (66)
Lunds universitet (38)
Umeå universitet (34)
Linköpings universitet (16)
visa fler...
Kungliga Tekniska Högskolan (13)
Örebro universitet (10)
Chalmers tekniska högskola (10)
Linnéuniversitetet (6)
Stockholms universitet (5)
Karlstads universitet (4)
Jönköping University (2)
Högskolan i Gävle (2)
Sveriges Lantbruksuniversitet (2)
Luleå tekniska universitet (1)
Mittuniversitetet (1)
Högskolan i Skövde (1)
Södertörns högskola (1)
Gymnastik- och idrottshögskolan (1)
Försvarshögskolan (1)
visa färre...
Språk
Engelska (709)
Svenska (3)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (123)
Naturvetenskap (36)
Lantbruksvetenskap (8)
Samhällsvetenskap (7)
Teknik (4)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy